---
title: "DEFeAT randomized trial: mineral-enriched powder for iron deficiency in reproductive-age women"
id: "medrxiv-13-dietary-enhancement-for-iron-deficiency-and-anaemia-treatment-defeat-study"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-dietary-enhancement-for-iron-deficiency-and-anaemia-treatment-defeat-study"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.20.26365734v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# DEFeAT randomized trial: mineral-enriched powder for iron deficiency in reproductive-age women
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-dietary-enhancement-for-iron-deficiency-and-anaemia-treatment-defeat-study
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.20.26365734v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The DEFeAT trial is a single-centre, randomised, double-blinded, placebo-controlled study enrolling 150 biologically female participants diagnosed with **iron deficiency** to test a home beverage fortification strategy. - Participants will be allocated to an active arm receiving an **electrolytic iron** and zinc sulphate monohydrate-containing powder or to a placebo arm for six months. - The study team reported the primary outcomes as change in **serum ferritin** concentrations and the proportion remaining iron deficient at six months. - Secondary outcomes include change in **haemoglobin** and serum ferritin over time, circulating metabolite and pro-inflammatory biomarker levels, dietary intake changes, self-reported health perceptions, palatability, adherence, safety outcomes and an economic assessment of cost-effectiveness. - Exploratory outcomes will profile the gut microbial metagenome and metabolome. - Trial registration is listed as NCT05990166; ethical approvals were obtained from four institutional boards and Health Canada provided Clinical Trial Application Authorization. - The source described the mineral ingredients (electrolytic iron; zinc sulphate monohydrate, small particle size) but did not report specific dosing amounts, daily administration details, placebo composition, or the statistical power calculation beyond the planned sample size. - Funders include Lucky Iron Life Enterprise, Inc., NRC IRAP, and a Natural Products Canada innovation grant. - Data were not presented in the preprint; this document reports a protocol and did not include generated trial results or participant-level data.
## Clinical Analysis & Structured Key Points
Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age | medRxiv Skip to main content Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age Jessie L Burns , Hailey Scott , Lawrence Mbuagbaw , Clara H Miller , Hauna Sheyholislami , Brianne A Clouthier , View ORCID Profile Bénédicte Fontaine-Bisson , Kristin L Connor doi: https://doi.org/10.64898/2026.10.20.26365734 Jessie L Burns 1 Carleton University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hailey Scott 1 Carleton University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lawrence Mbuagbaw 2 McMaster University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Clara H Miller 1 Carleton University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hauna Sheyholislami 1 Carleton University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Brianne A Clouthier 3 Renfrew Medical Group; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bénédicte Fontaine-Bisson 4 University of Ottawa Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bénédicte Fontaine-Bisson Kristin L Connor 1 Carleton University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: kristin.connor{at}carleton.ca Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Iron deficiency (ID) and iron deficiency anaemia (IDA) have global and severe health implications, and disproportionately impact women of reproductive age. Current methods of supplementing diets with iron are challenged by poor adherence and palatability, reducing effectiveness of these treatment strategies. The aim of this study is to evaluate the efficacy of a novel home beverage fortification with a mineral-enriched powder, designed to enhance bioavailability and ease of use, for the treatment of ID in women of reproductive age. Methods: This single-centre, randomised, double-blinded placebo-controlled trial will enrol 150 eligible biologically female participants with ID. Participants will be randomly assigned to the active intervention (iron/zinc-enriched powder) or control group (placebo powder) over 6 months. Primary outcomes will include change in serum ferritin (SF) concentrations and proportion of participants who remain iron deficient at 6-months. Secondary outcomes will include change in SF and haemoglobin (Hb) concentrations across timepoints, and levels of metabolites and key circulating pro-inflammatory biomarkers, changes in dietary intakes, self-reported perceptions of health, barriers to use of the powder, adherence and palatability, safety outcomes, and cost-effectiveness. Exploratory outcomes will assess the gut microbial metagenome and metabolome. Discussion: Fortification, an effective approach for the prevention of ID/IDA, has advantages over some methods of supplementation because it uses low levels of iron, minimising unpleasant side effects, does not risk toxicity, and has high acceptability and compliance rates. This mineral-enriched powder uses electrolytic iron and zinc sulphate monohydrate of a small particle size, which is less irritating to the gut, and facilitates bioavailability. Findings from the study will be shared with those affected by and involved in treating these conditions, as a novel intervention that is both effective and acceptable among women of reproductive age would help to improve treatment compliance, and ultimately, reduce ID/IDA burden. Trial registration: This trial is registered at clinicaltrials.gov ( NCT05990166 ): https://clinicaltrials.gov/study/ NCT05990166 , August 2023. Competing Interest Statement The authors have declared no competing interest. Clinical Trial NCT05990166 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Montfort Hospital Research Ethics Board (#22-23-07-017), the Carleton University Research Ethics Board (#118907), University of Ottawa Research Ethics Board (#H-01-23-8256), and the Algonquin College Research Ethics Board (#2024-Feb-Connor) gave ethical approval of this work. The protocol has also received Clinical Trial Application Authorisation from Health Canada's Natural and Nonprescriptive Health Products Directorate (protocol number: LIFe2022RCT2, file number: 257665). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Not applicable. This manuscript does not report data generation or analysis. Funder Information Declared Lucky Iron Life Enterprise, Inc National Research Council of Canada Industrial Research Assistance Programme , NRC IRAP; 21P75C1 Innovation development grant from Natural Products Canada Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age Jessie L Burns , Hailey Scott , Lawrence Mbuagbaw , Clara H Miller , Hauna Sheyholislami , Brianne A Clouthier , Bénédicte Fontaine-Bisson , Kristin L Connor medRxiv 2026.10.20.26365734; doi: https://doi.org/10.64898/2026.10.20.26365734 Share This Article: Copy Citation Tools Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age Jessie L Burns , Hailey Scott , Lawrence Mbuagbaw , Clara H Miller , Hauna Sheyholislami , Brianne A Clouthier , Bénédicte Fontaine-Bisson , Kristin L Connor medRxiv 2026.10.20.26365734; doi: https://doi.org/10.64898/2026.10.20.26365734 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (632) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4939) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (670) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1665) Epidemiology (16149) Forensic Medicine (35) Gastroenterology (1234) Genetic and Genomic Medicine (7203) Geriatric Medicine (747) Health Economics (1088) Health Informatics (5215) Health Policy (1454) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16421) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (738) Neurology (7483) Nursing (375) Nutrition (1112) Obstetrics and Gynecology (1278) Occupational and Environmental Health (1028) Oncology (3707) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (491) Palliative Medicine (142) Pathology (716) Pediatrics (1844) Pharmacology and Therapeutics (748) Primary Care Research (780) Psychiatry and Clinical Psychology (6062) Public and Global Health (9907) Radiology and Imaging (2497) Rehabilitation Medicine and Physical Therapy (1498) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Serum IL-6, IL-10 and IL6/IL10 Genotypes in Bangladeshi Patients with Diabetic Neuropathy](https://medichelpline.com/clinical-feed/plos-one-14-association-of-il-6-and-il-10-serum-levels-with-genetic-variants-in-diabetic.md)
- [Psychosocial profile in adults with congenital heart disease by documented anxiety disorder history](https://medichelpline.com/clinical-feed/plos-one-21-psychosocial-profile-of-adults-with-congenital-heart-disease-according-to.md)
- [Safety and Immunogenicity of the GBS-AlpN Vaccine in Adults 55–75: Phase 1 Randomised Trial](https://medichelpline.com/clinical-feed/pubmed-42759245.md) (DOI: 10.1016/j.vaccine.2026.129133)
- [Seasonal influenza vaccination coverage and population health burden in Europe: ecological panel a](https://medichelpline.com/clinical-feed/pubmed-42759249.md) (DOI: 10.1016/j.vaccine.2026.129163)
- [Moderna–Merck melanoma vaccine data leaked before ESMO presentation](https://medichelpline.com/clinical-feed/stat-news-0-stat-highly-anticipated-moderna-merck-melanoma-cancer-vaccine-data-arrived-early.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.